Clinical Trials Directory

Trials / Completed

CompletedNCT00839293

Comparison of Fenofibric Acid Bioavailability From ABT-335 Capsules

Comparison of Fenofibric Acid Bioavailability From 45 mg and 135 mg Strength ABT-335 Capsules

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
32 (estimated)
Sponsor
Abbott · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to evaluate the safety and compare the bioavailability of fenofibric acid from 2 different dosage strengths of ABT-335.

Conditions

Interventions

TypeNameDescription
DRUGABT-335Once, see arm description for more information

Timeline

Start date
2009-02-01
Primary completion
2009-03-01
First posted
2009-02-09
Last updated
2010-10-15

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00839293. Inclusion in this directory is not an endorsement.

Comparison of Fenofibric Acid Bioavailability From ABT-335 Capsules (NCT00839293) · Clinical Trials Directory